Gilead Sciences (GILD) Saham Harga
Gilead Sciences Harga
Selama 19 tahun terakhir pendapatan Gilead Sciences tumbuh 12,7% per tahun, mencapai 29,44 miliar USD. Laba per saham tumbuh 12,1% per tahun selama 18 tahun terakhir. Bagi Gilead Sciences, margin bersih sebesar 28,9% naik dibanding 22,8% beberapa tahun lalu. Pada harga saat ini imbal hasil dividen sekitar 1,89%. Rasio pembayaran sekitar 47% dari laba. Dividen tumbuh 9,4% per tahun selama 10 tahun terakhir. Target harga konsensus 12 bulan untuk Gilead Sciences adalah 155,00 USD, sekitar di bawah harga saat ini 7,5%. Dari 36 analis, 30 merekomendasikan beli — konsensus keseluruhan Beli.
Harga saham Gilead Sciences
Akses data ini lewat Eulerpool API
100.000 permintaan/bulan gratis · tanpa kartu
Model bisnis dan analisis saham Gilead Sciences
Pertanyaan yang sering diajukan tentang saham Gilead Sciences
Gilead Sciences Inc is a biopharmaceutical company with a diversified business model. Its primary focus is on the research, development, and commercialization of innovative medications to treat and prevent life-threatening diseases. Gilead operates in multiple therapeutic areas, including HIV/AIDS, liver diseases, hematology/oncology, respiratory, cardiovascular, and viral infections. The company's business model revolves around discovering and designing new drugs, conducting clinical trials, obtaining regulatory approvals, manufacturing, marketing, and distribution of its pharmaceutical products. Through strategic collaborations and acquisitions, Gilead continuously expands its portfolio and aims to improve the quality of life for patients worldwide.
Gilead Sciences Inc is primarily active in the pharmaceutical industry.
The main competitors of Gilead Sciences Inc in the market include renowned companies like AbbVie, Bristol-Myers Squibb, and Merck & Co. These pharmaceutical giants operate in similar therapeutic areas and engage in the research, development, and commercialization of innovative medicines. At present, Gilead Sciences Inc faces competition in the fields of antiviral drugs, liver diseases, HIV/AIDS treatments, and oncology from these prominent industry players.
Gilead Sciences Inc, a leading biopharmaceutical company, was founded in 1987 by Dr. Michael L. Riordan in Foster City, California, USA. It specializes in discovering, developing, and commercializing innovative medicines to address unmet medical needs. Gilead has a rich history of pioneering breakthrough treatments for critical diseases such as HIV/AIDS, hepatitis, and other viral infections. With a mission to advance patient care globally, Gilead has expanded its portfolio through strategic acquisitions and collaborations, constantly striving to improve and save lives. Today, Gilead Sciences Inc remains committed to research, development, and manufacturing of transformative therapies across various therapeutic areas.
Gilead Sciences Inc has achieved several significant milestones throughout its history. It gained global recognition with the development of groundbreaking antiviral drugs such as Sovaldi and Harvoni, revolutionizing the treatment of hepatitis C. The company also made remarkable progress in the field of HIV, introducing a single-tablet regimen named Genvoya, providing convenient and effective therapy. Gilead Sciences Inc further expanded its therapeutic areas, bringing forth innovative treatments for life-threatening diseases like cancer and autoimmune disorders. Moreover, it received approval for its antiviral drug, remdesivir, as a treatment for COVID-19. These milestones solidify Gilead Sciences Inc's position as a leader in the pharmaceutical industry.
Gilead Sciences Inc is primarily present in various countries and regions worldwide. Some key locations where the company has a strong presence include the United States, Europe (including countries like Germany, France, and the United Kingdom), Asia-Pacific (including countries like Japan, Australia, and China), and Latin America (including countries like Brazil and Mexico). With a global footprint, Gilead Sciences Inc operates in multiple markets, providing its innovative biopharmaceutical products and therapies to patients across different continents.
Gilead Sciences Inc represents a commitment to improving the lives of patients through innovative research and development in the fields of life sciences and biotechnology. Their corporate philosophy emphasizes a patient-centered approach, scientific integrity, and a drive to address unmet medical needs. Gilead Sciences Inc focuses on developing breakthrough therapies and treatments to combat diseases such as HIV/AIDS, viral hepatitis, and other challenging illnesses. They prioritize collaboration with healthcare professionals and stakeholders to ensure the delivery of high-quality healthcare solutions. With a strong emphasis on scientific excellence and a dedication to addressing global health challenges, Gilead Sciences Inc continues to make a significant impact in the industry.
Analis saat ini menetapkan target harga rata-rata 153,33 USD untuk saham Gilead Sciences (median: 155,00 USD), yaitu -8,5 % terhadap harga terbaru. Konsensus didasarkan pada 36 peringkat analis.
36 analis saat ini menilai saham Gilead Sciences: 30 merekomendasikan beli, 6 tahan, dan 0 jual. Untuk 2026, analis memperkirakan Gilead Sciences menghasilkan pendapatan 30,78 miliar USD dan laba per saham -0,40 USD.
Dengan kurs saat ini, saham Gilead Sciences diperdagangkan pada 150,16 EUR (167,57 USD).
Saham Gilead Sciences (GILD) tercatat di 10 bursa, termasuk: NASDAQ (GILD), London (0QYQ.L), SIX (Zürich) (GILD.SW), XETRA (GIS.DE), Frankfurt (GIS.F), München (GIS.MU), Düsseldorf (GIS.DU), Hamburg (GIS.HM).
Gilead Sciences Inc is a biopharmaceutical company that develops innovative therapies for serious diseases such as HIV, hepatitis B and C, cancer, lung and liver diseases. The company is headquartered in Foster City, California and has been publicly traded since 1987. Gilead operates worldwide and has offices in more than 30 countries. The business model of Gilead Sciences is based on the development, manufacturing and marketing of innovative drugs. The company specializes in discovering chemicals that enable effective treatment of diseases. In recent years, Gilead Sciences has focused on the development of drugs for hepatitis C and HIV, which has contributed to significant revenue growth. Gilead Sciences' products are divided into three divisions: 1. Infectious Diseases: This division includes drugs for the treatment of HIV, hepatitis B and C, and other infectious diseases. The most well-known and successful drug is Viread, used for the treatment of HIV and hepatitis B. Another promising drug is Harvoni, a combination of two active ingredients used to treat hepatitis C. 2. Oncology: This division includes drugs for the treatment of various types of cancer, such as multiple myeloma, non-Hodgkin's lymphoma, and chronic lymphocytic leukemia. The most well-known drug is Revlimid, used for the treatment of multiple myeloma and other types of cancer. 3. Inflammatory and respiratory diseases: This division includes drugs for the treatment of conditions such as rheumatoid arthritis, Crohn's disease, and emphysema. The most well-known drug is Remicade, used for the treatment of inflammatory bowel disease. In recent years, Gilead Sciences has established itself as a leading biopharmaceutical company through significant acquisitions and acquisitions. For example, in 2017, Kite Pharma, a company specializing in cancer immunotherapy, was acquired for $11.9 billion. This acquisition allowed Gilead Sciences to expand its portfolio of oncology drugs and strengthen its market position. Gilead Sciences' business model is based on a strong research and development department that continuously discovers and introduces new drugs to the market. Gilead Sciences has a broad pipeline of drugs in development to provide effective treatment for serious diseases to patients worldwide. The company works closely with regulatory authorities to expedite the approval of new drugs. Overall, Gilead Sciences Inc is an innovative and successful biopharmaceutical company specializing in the development and marketing of drugs for the treatment of serious diseases. The company has established itself as a leading provider in this field in recent years and will continue to play a crucial role in the development of new therapies in the future.
Pendapatan diperkirakan dari Gilead Sciences adalah 30,78 miliar USD. Angka ini didasarkan pada data keuangan terkini dan mencerminkan kinerja bisnis perusahaan.
Laba diperkirakan dari Gilead Sciences adalah -500,02 Juta. USD. Laba bersih mencerminkan profitabilitas perusahaan setelah mengurangi semua biaya.
Rasio harga-terhadap-pendapatan (PER) Gilead Sciences saat ini adalah -419,92. PER membandingkan harga saham saat ini dengan laba per saham dan membantu investor menilai valuasi saham Gilead Sciences.
Rasio harga-terhadap-penjualan (PSR) Gilead Sciences saat ini adalah 6,82. PSR membandingkan kapitalisasi pasar dengan pendapatan tahunan dan berfungsi sebagai metrik valuasi untuk saham Gilead Sciences.
Skor Kualitas AlleAktien untuk Gilead Sciences adalah 5/10.
ISIN dari Gilead Sciences adalah US3755581036. ISIN (International Securities Identification Number) adalah identifikasi unik global untuk sekuritas.
WKN dari Gilead Sciences adalah 885823. WKN (Wertpapierkennnummer) adalah kode identifikasi sekuritas Jerman enam digit.
Ticker dari Gilead Sciences adalah GILD. Simbol ticker digunakan untuk memperdagangkan saham Gilead Sciences di bursa saham.
Saham Gilead Sciences
Kelompok Peer Gilead Sciences
Gilead Sciences Ticker
Gilead Sciences FIGI
Semua metrik fundamental dan analisis mendalam Gilead Sciences
Analisis saham kami untuk saham Gilead Sciences mencakup kalkulasi keuangan penting seperti pendapatan, keuntungan, P/E ratio (P/E), P/S ratio (P/S), EBIT, serta informasi tentang dividen. Selain itu, kami juga mengamati aspek-aspek seperti saham, kapitalisasi pasar, utang, ekuitas, dan kewajiban dari Gilead Sciences. Jika Anda mencari informasi lebih rinci tentang topik-topik ini, kami menawarkan analisis terperinci di subhalaman kami.